01—Abstract
Summary
Summary of the 10-Q filed August 1, 2023. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. (LDOS) reported higher revenue and profitability for the second quarter and first half of fiscal 2023.
Revenues for the three months ended June 30, 2023 were $3,838 milliona, up from $3,597 million a year earlier, and operating income rose to $331 million from $271 million. For the six months, revenues were $7,537 million versus $7,091 million, and operating income was $596 million versus $542 million. Net income attributable to Leidos common stockholders was $207 million for the quarter, with diluted EPS of $1.50 versus $1.24.
Operating margin was 8.6% for the quarter compared with 7.5% in the prior-year quarter. Defense Solutions, Civil and Health all reported higher revenues for the quarter, and Health's operating income declined year over year due to a prior-year $28 millionb COVID-19 stop-work recovery. Cash flow and balance sheet activity were more mixed.
Net cash provided by operating activities was $66 millionc for the six months, down from $138 million, reflecting higher tax payments. Total debt was $4.9 billion at June 30, 2023, unchanged from year-end. During the first quarter, Leidos issued $750 million of 5.75% senior notes due 2033 and entered into a $1.0 billion term loan facility and a $1.0 billion revolving facility, both maturing in March 2028.
Cash and cash equivalents were $329 milliond. The company paid $0.36 per share in quarterly dividends and made no share repurchases in the second quarter. Total backlog was $34,152 million at June 30, 2023, compared with $34,722 million a year earlier, and second-quarter net bookings were $2.9 billion.
Investors should note several disclosed legal and regulatory matters. The company is conducting an internal investigation into international operations that it has self-reported to the Department of Justice and the SEC, and it received a federal grand jury subpoena in connection with that matter.
A separate grand jury subpoena from the Department of Justice Antitrust Division relates to three U.S. Government procurements. The company also holds a potential interest in VirnetX patent litigation proceeds, but the filing states that no assurances can be given when or if any proceeds will be received.
02—Key points
Key Highlights
- Q2 2023 revenues of $3,838 million, up from $3,597 million; six-month revenues of $7,537 million versus $7,091 million
- Q2 2023 operating income of $331 million versus $271 million, with operating margin of 8.6% compared with 7.5%
- Q2 2023 diluted EPS of $1.50 versus $1.24; six-month diluted EPS of $2.67 versus $2.49
- Operating cash flow for the six months fell to $66 million from $138 million, mainly due to higher tax payments tied to the TCJA research and development provision
- Refinanced debt in early 2023 with $750 million 5.75% senior notes due 2033 and a $1.0 billion term loan and $1.0 billion revolver maturing in March 2028; total debt of $4.9 billion at June 30, 2023
- Total backlog of $34,152 million and Q2 net bookings of $2.9 billion; remaining performance obligations of $13.9 billion
- Ongoing DOJ/SEC-related internal investigation of international operations and a DOJ Antitrust Division grand jury subpoena remain open matters
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Leidos Holdings kept $0.05.
- Revenue$3.81B100.0%
- Cost of revenue−$3.27B85.8%
- Gross profit$542.0M14.2%
- Operating costs−$211.0M5.5%
- Operating income$331.0M8.7%
- Interest, other & tax−$124.0M3.3%
- Net income$207.0M5.4%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2023Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $3.81B$3.57B | +6.9% |
| Cost of Revenue | $3.27B$3.06B | +6.9% |
| Gross Profit | $542.00M$508.00M | +6.7% |
| SG&A Expenses | $237.00M$262.00M | −9.5% |
| Operating Income | $331.00M$271.00M | +22.1% |
| Net Income | $207.00M$171.00M | +21.1% |
| EPS (Basic) | $1.51$1.25 | +20.8% |
| EPS (Diluted) | $1.50$1.24 | +21.0% |
| Shares Outstanding (Basic) | 137.00M137.00M | 0.0% |
| Shares Outstanding (Diluted) | 138.00M138.00M | 0.0% |
05—Questions
Frequently Asked Questions
How did Leidos perform in the second quarter of 2023?
Revenues rose to $3,838 million from $3,597 million, and operating income increased to $331 million from $271 million. Net income attributable to Leidos common stockholders was $207 million, and diluted EPS was $1.50 compared with $1.24 a year earlier. Operating margin was 8.6% versus 7.5%.
How is the company's debt structured after its 2023 refinancing?
In February 2023 Leidos issued $750 million of 5.75% senior notes due March 2033. In March 2023 it entered into a Credit Agreement providing a $1.0 billion senior unsecured term loan and a $1.0 billion senior unsecured revolving facility, both maturing in March 2028. Proceeds were used to repay the $1.9 billion term loan facility and the $750 million revolving facility. Total debt was $4.9 billion at June 30, 2023, and no revolver borrowings were outstanding.
Why did operating cash flow decline in the first half of 2023?
Net cash provided by operating activities was $66 million for the six months, compared with $138 million a year earlier. The filing attributes the decline mainly to higher tax payments of $152 million, largely related to the TCJA provision on research and development costs, and a $62 million payment for payroll taxes related to the CARES Act. Strong trade receivable collections and favorable timing of customer advance payments partially offset these outflows.
What legal and regulatory matters could affect Leidos?
The company is conducting an internal investigation into conduct in a portion of its international operations, which it has self-reported to the Department of Justice and the SEC. A federal grand jury subpoena was received in September 2022 related to a U.S. Attorney's Office criminal investigation, and a former employee was indicted in February 2023. Separately, a August 2022 grand jury subpoena from the DOJ Antitrust Division concerns three U.S. Government procurements. The filing states it cannot predict the timing, outcome or possible impact of these matters.
What is the status of the VirnetX litigation proceeds?
Under its agreements with VirnetX, Leidos would receive 25% of proceeds obtained by VirnetX after attorneys' fees and costs. However, the Federal Circuit vacated the Apple II district court judgment on March 31, 2023 and remanded it with instructions to dismiss as moot, and it affirmed USPTO findings that certain patent claims are unpatentable. VirnetX's rehearing petitions were denied in June 2023. The filing states that no assurances can be given when or if Leidos will receive any proceeds.
06—Continue